Clinical Oncologist, proud Sri Lankan 🇱🇰
Joined September 2011
- Tweets83
- Following147
- Followers54
- Likes376
Vimukthini Peiris retweeted
The SLCO Regional Session in #Rathnapura, an initiative of the #YoungOncologistsForum of #SLCO, successfully brought together healthcare professionals through parallel #Oncology #Doctors' and #Nursing Sessions, promoting education, collaboration, and better #cancercare.
21st #AnnualAcedemicSessions of @slconcology kicks off to an auspicious start! @hiprabs @sidathwijeseke1 – at Sri Lanka
Vimukthini Peiris retweeted
Have u ever seen curves as wide as this for any drug recently? Lorlatinib for metastatic ALK positive NSCLC. Great results 👏. It works With reduced dose also. Let's hope it becomes more accessible. @asco #asco24 @OncoAlert @OncBrothers @Larvol @Alfdoc2 @JackWestMD @brunolarvol
Vimukthini Peiris retweeted
WOW!
HPV ctDNA detection at 3 months after dCRT for anal canal cancer associated with 100% risk of recurrence!
8% with HPV ctDNA negative
#ASCO24
Vimukthini Peiris retweeted
MONARCH 3: Final overall survival results
🔍mFU: 8.1 years (OS: secondary endpoint)
mOS➡️66.8 vs 53.7 mo (HR:0.8, p:0.06)
💥The absolute difference was 13.1 months but did not reach statistical significance
@Annals_Oncology @OncoAlert
annalsofoncology.org/article…
Vimukthini Peiris retweeted
The standard of care for stage III NSCLC changes once again;
Say goodbye to Durvalumab for patients with mEGFR (ex19del & L858R). #radonc
astrazeneca.com/media-centre…
Vimukthini Peiris retweeted
TiP: EA8211-SOAR: Non-inferiority phase 3 trial of SABR vs systemic therapy for metachronous (pre-treated) oligometastatic RCC (2-5 mets, IMDC fav-int risk)
🔷SABR arm: Systemic therapy only following progression
🔷Co-primary: OS & Gr≥3 toxicity
🔷Secondary: QoL, PFS, cost-effectiveness, ctDNA correlatives
@urotoday #GU24
Vimukthini Peiris retweeted
1/N Finally out!! -- 30Gy for HPV+OPC in @JCO_ASCO
– work by the @MSKCancerCenter Head and Neck team, led by @imrtlee, Eric Sherman, and myself on using hypoxia imaging response to cut treatment 60% (70->30Gy)! #radonc #hncsm ascopubs.org/doi/10.1200/JCO…
Vimukthini Peiris retweeted
✨Join us at NCISL where a star studded cast will discuss the latest advancements in #Oncology organised by the @CSSL_AAS and @slconcology in collaboration with @TataMemorial Centre #India✨
24th January 2024.
@prasaday @Dr_Pawan_Rane @Shrikhande_SV
Vimukthini Peiris retweeted
In Sri Lanka there's this massive column of rock nearly 200 m high that hosts a 1600-year-old fortress on its top
[read more: buff.ly/48g9IVX]
Vimukthini Peiris retweeted
Wishing you a year filled with strength, resilience, and healing. Happy New Year!
#NewYear #2024NewYear
Vimukthini Peiris retweeted
📌Watch our eminent consultant oncologist @nuradh speak on #breastcancer 🇱🇰
#BreastCancerAwareness
@adaderana
fb.watch/o63KIjHROj/
Vimukthini Peiris retweeted
"No matter what obstacles we encounter, we owe it to our patients not to allow the high standards we have upheld thus far, to diminish. Therefore, excellence should remain our ultimate goal in all that we do"
Inspiring words by #SLCO president @prasaday
sundaytimes.lk/231029/news/i…
Honoured to have been given the #opportunity be a part of the 4th batch of #LeadershipDevelopment program of @faro_asia. Thank you #FARO and @slconcology!
Vimukthini Peiris retweeted
I've used this widely in my practice due to resource constraints with excellent results.. #hypofractionation #headandneckcancer @slconcology @slcancer @Vimukthini
HYPNO trial confirms non-inferiority of 55/20 to conventional fractionation with cisplatin👏🏽 As a registrar 55/20 was our SoC for #headandneck cancer. My favourite study today! #Moderatehypofractionation strikes again! #ASTRO23 @ASTRO_org @SorenBentzen @iaeaorg #optimalcare
Vimukthini Peiris retweeted
Twice daily radiotherapy to 54Gy BID ⬆️⬆️ OS and PFS in small cell #lungcancer as compared to 45Gy BID. compared to CONVERT and RTOG, higher once daily RT did not ⬆️ OS. #lcsm - abstract ➡️ shorturl.at/huDJ2 - time to change?
Vimukthini Peiris retweeted
This is absolutely brilliant. Not only is the data compelling, @_ShankarSiva, but it is presented in a manner that I feel may be quite conducive to sharing with my patients for discussion (thoughts, @LauraEsfeller @DebMaskens @RCCadvocate @advocatekidneys?). Your talk at #ASTRO23 not only validates a terrific option for pts 👏 but could provide all of us in academics a better way to practically convey information.
🧵1/ 🙏🏾🙏🏾Thank you patients, families, trial staff and investigators for participating in @TROGfightcancer
15.03 FASTRACK II! This trial recruited n=70 across 8 sites in 🇦🇺 and 🇳🇱 #ASTRO23! #radonc #kcsm #radiotherapy @ANZUPtrials @KidneyCancer
Vimukthini Peiris retweeted
October is #BreastCancer #Awareness month. The commonest cancer among women in #SriLanka it is eminently curable if detected early. @SlCancer @indira_trust #lka
